Chelsea Therapeutics International Ltd. (CHTP) Looks Strong as Stock Shoots up 31.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 09, 7:44AM CDT
Chelsea Therapeutics International Ltd. (CHTP) was a big mover last session, as the company saw its shares soar 31.6% on the day.
VIVUS Inc. (VVUS) in Focus: Stock Rises 7.23% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed May 07, 7:44AM CDT
VIVUS Inc. (VVUS) was a big mover last session, as the company saw its shares rally over 7% on the day.
Endocyte, Inc. (ECYT) in Focus: Stock Rises 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue May 06, 7:44AM CDT
Endocyte, Inc. (ECYT) was a big mover last session, as the company saw its shares rally nearly 6% on the day.
Trovagene Schedules Release of First Quarter 2014 Financial Results and Investor Conference Call
PR Newswire - Mon May 05, 3:00PM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it will report financial results for the quarter ended March 31, 2014 on Monday, May 12, 2014 at 4:00 p.m. Eastern Daylight Time (1:00 p.m. Pacific Daylight Time).
Sequenom Inc. (SQNM) in Focus: Stock Rallies 8.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon May 05, 7:44AM CDT
Sequenom Inc. (SQNM) was a big mover last session, as the company saw its shares rally nearly 9.00% on the day.
Merrimack Pharmaceuticals, Inc. (MACK) Appears Robust as Stock Shoots up 59.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 02, 7:44AM CDT
Merrimack Pharmaceuticals, Inc. (MACK) was a big mover last session, as the company saw its shares surge a whopping 59.2% on the day
Strength Seen in Avanir Pharmaceuticals, Inc. (AVNR) as Stock Shoots up 45.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 01, 7:44AM CDT
Avanir Pharmaceuticals, Inc. (AVNR) was a big mover last session, as the company saw its shares surge a whopping 45.6% on the day.
Amicus Therapeutics (FOLD) Jumps: Stock Up 20.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 8:39AM CDT
Amicus Therapeutics, Inc. (FOLD) was a big mover last session, as its shares rose nearly 21% on the day.
GTX Inc. (GTXI) Jumps: Stock Up 14.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 7:51AM CDT
GTX Inc. (GTXI) was a big mover last session, as its shares rose over 14% on the day.
Nasdaq stocks posting largest percentage increases
AP - Tue Apr 29, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Revance Therapeutics (RVNC) Soars: Stock Up 25.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 8:39AM CDT
Revance Therapeutics, Inc. was a big mover last session, as its shares rose nearly 26% on the day.
Cytokinetics, Incorporated (CYTK) Jumps: Stock Up 13.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 8:39AM CDT
Cytokinetics, Incorporated was a big mover last session, as its shares rose nearly 14% on the day.
Sarepta Therapeutics (SRPT) Soars: Stock Up 39.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 7:51AM CDT
Sarepta Therapeutics, Inc. was a big mover last session, as its shares rose over 39% on the day.
TrovaGene (TROV) Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 10:47AM CDT
TrovaGene (TROV) Enters Oversold Territory
Clinical Data Presented at AACR Demonstrate Ability of Trovagene's Molecular Diagnostic Platform to Non-Invasively Track Cancer Patients' Response to Therapy
PR Newswire - Tue Apr 08, 10:00AM CDT
Clinical study results presented today at the American Association for Cancer Research (AACR) Annual Meeting demonstrate the ability of Trovagene's (NASDAQ: TROV) molecular diagnostic platform to detect and monitor BRAF V600E mutations in cancer patients. The results were presented by Filip Janku, M.D., Ph.D., of The University of Texas MD Anderson Cancer Center.
Trovagene Announces Clinical Data Presentation for Its Oncogene Mutation Monitoring Platform at the American Association for Cancer Research Annual Meeting
PR Newswire - Tue Apr 01, 7:00AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that clinical data from a study using the company's cancer monitoring platform for the detection and longitudinal monitoring of BRAF V600E mutations will be the subject of a late-breaking poster presentation at the American Association for Cancer Research Annual Meeting in San Diego, California.
Trovagene names Dr Charles Cantor to SAB
M2 - Thu Mar 27, 6:10AM CDT
Molecular diagnostics company Trovagene (NASDAQ:TROV) disclosed on Wednesday that Charles Cantor PhD, has been elected to its Scientific Advisory Board (SAB).
Genomics and Molecular Diagnostics Pioneer Charles Cantor, Ph.D., Joins Trovagene's Scientific Advisory Board
PR Newswire - Wed Mar 26, 7:00AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that Charles Cantor, Ph.D., has joined the Company's Scientific Advisory Board. Dr. Cantor, one of the leaders of the Human Genome Project, has published more than 400 peer reviewed articles, authored and co-authored more than 50 U.S. and international patents, and is also an author of the first genomics textbook, Genomics: The Science and Technology of the Human Genome Project.
Trovagene and Catholic Health Initiatives Center for Translational Research Partner to Clinically Evaluate Non-Invasive Genomic Diagnostics to Improve Cancer Care
PR Newswire - Wed Mar 19, 7:00AM CDT
Trovagene, Inc. (NASDAQ: TROV) and Catholic Health Initiatives Center for Translational Research (CTR) today announced they have entered into a strategic partnership to conduct clinical validation studies, clinical utility studies, health economic studies, and other activities to determine the effectiveness of Trovagene's urine-based cell-free DNA cancer monitoring diagnostics in clinical practice. CTR is a limited liability company whose sole corporate member is Catholic Health Initiatives Institute for Research and Innovation (CIRI), a direct subsidiary of Catholic Health Initiatives (CHI). Englewood Colorado-based CHI is one of the nation's largest health systems, operating in 18 states and comprising 87 hospitals, including four academic medical centers and teaching hospitals and 24 critical-access facilities.